KaloBios files for a $60 million IPO

Comment

Shutterstock photo

KaloBios, a biopharmaceutical focused on therapeutics that treat respiratory diseases and cancer, filed on Friday with the SEC to raise up to $60 million in an initial public offering. The South San Francisco, CA-based company, which was founded in 2001 and booked $18 million in sales for the 12 months ended 6/30/2012, plans to list on the NASDAQ under the symbol KBIO. Leerink Swann is the sole bookrunner on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines IPOs
Referenced Stocks: KBIO


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com